Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Accumulated Depreciation (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Accumulated Depreciation for 7 consecutive years, with $83.2 million as the latest value for Q2 2025.

  • On a quarterly basis, Accumulated Depreciation changed N/A to $83.2 million in Q2 2025 year-over-year; TTM through Jun 2025 was $83.2 million, a N/A change, with the full-year FY2024 number at $72.1 million, up 43.69% from a year prior.
  • Accumulated Depreciation was $83.2 million for Q2 2025 at Beam Therapeutics, up from $77.6 million in the prior quarter.
  • In the past five years, Accumulated Depreciation ranged from a high of $83.2 million in Q2 2025 to a low of $10.3 million in Q1 2021.
  • A 5-year average of $39.2 million and a median of $32.5 million in 2022 define the central range for Accumulated Depreciation.
  • Peak YoY movement for Accumulated Depreciation: soared 92.03% in 2022, then skyrocketed 43.69% in 2024.
  • Beam Therapeutics' Accumulated Depreciation stood at $16.1 million in 2021, then skyrocketed by 87.61% to $30.2 million in 2022, then surged by 66.33% to $50.2 million in 2023, then surged by 43.69% to $72.1 million in 2024, then increased by 15.35% to $83.2 million in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Accumulated Depreciation are $83.2 million (Q2 2025), $77.6 million (Q1 2025), and $72.1 million (Q4 2024).